Advanced search×

Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease.

Edward V EV Loftus, Scott J SJ Johnson, Si-Tien ST Wang, Eric E Wu, Parvez M PM Mulani, and Jingdong J Chao

Inflamm Bowel Dis 17(1):127-40 (2011) PMID 20848523

Adalimumab is indicated for the treatment of moderately to severely active Crohn's disease (CD). A systematic analysis of risks and benefits of adalimumab versus traditional non-biologic therapies for patients refractory to non-biologic therapy is lacking.

DOI: 10.1002/ibd.21341
Version: za2963e q8za1 q8zb5 q8zc4 q8zd7 q8zed q8zfb q8zg2

Similar articles you may find interesting…

  1. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis.
    Patrick S Parfrey, Maria Lauve, ... Patrick Lefebvre

    Clin J Am Soc Nephrol 4(4):755-62 (2009) PMID 19339417

    View PDF
  2. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.
    E V EV Loftus, S V SV Kane, and D D Bjorkman

    Aliment Pharmacol Ther 19(2):179-89 (2004) PMID 14723609

    Forty-six trials were included. One study of mesalazine vs. sulfasalazine for active colitis showed significantly fewer patients with adverse events with mesalazine. Both balsalazide vs. sulfasalazine studies for active disease showed significantly fewer withdrawals with balsalazide. One trial of ba...
  3. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis ...
    Geert R GR D'Haens, Remo R Panaccione, ... Simon S Travis

    Am J Gastroenterol 106(2):199-212; quiz 213 (2011) PMID 21045814

    The advent of biological therapy has revolutionized inflammatory bowel disease (IBD) care. Nonetheless, not all patients require biological therapy. Selection of patients depends on clinical characteristics, previous response to other medical therapy, and comorbid conditions. Availability, reimburse...